Tega Therapeutics
UEI: C1LJLCS3PM51
• CAGE: 6W1N1
Overview
Awardee Type
Parent
Company Description
TEGA Therapeutics produces recombinant heparan sulfate and enzyme replacement therapies for lysosomal storage diseases.
Name
Tega Therapeutics
Website
Headquarters
San Diego, CA
United States
United States
Most Recent Award
Sept. 1, 2024
Calculating
Federal grant recipient
TEGA THERAPEUTICS INC
(UEI C1LJLCS3PM51, CAGE 6W1N1)
is headquartered in San Diego CA.
Its primary registered NAICS is 622110 General Medical and Surgical Hospitals.
The corporation
was founded in March 2013 and
federally registered in
April 2013.
Federal Award Analysis
Tega Therapeutics federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
TEGA THERAPEUTICS INC
UEI
C1LJLCS3PM51
CAGE Code
6W1N1
Primary NAICS
SBA Certifications
None
Self Certifications
None
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
March 28, 2013
Initial Registration
April 16, 2013
Last Registration
Oct. 9, 2024
Registration Activation
Oct. 9, 2024
Registration Expiration
Oct. 7, 2025
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
State of Incorporation
DE
Country of Incorporation
USA
Employees
<500
Reported NAICS
Accepts Credit Cards
No
People
Vendor contacts at Tega Therapeutics
Grant Awards
Tega Therapeutics direct grants
Subgrant Awards
Tega Therapeutics subgrant awards
Teaming Partners
Disclosed awardee sub and prime contract and grant relationships
Tega Therapeutics